Latest News
-
Thursday - August 20, 2020
Bayer announces resolution of U.S. Essure™ claims » more
-
Tuesday - August 18, 2020
Bayer Names Sara Boettiger as Head of Global Public Affairs, Science and Sustainability for Crop Science Division » more
-
Wednesday - August 12, 2020
Bayer and Temasek unveil innovative new company focused on developing breakthroughs in vertical farming
Initial efforts will focus on innovating vegetable varieties that deliver optimized quality and sensory experience / Called Unfold, the new company will be headquartered in the Davis, Calif., area with key operations in both the U.S. and Singapore / John Purcell appointed as CEO » more
-
Tuesday - August 11, 2020
Not intended for U.S. and UK Media
Bayer to acquire UK-based biotech KaNDy Therapeutics Ltd.
Further expansion of Bayer’s drug development pipeline in Women’s Healthcare / Innovative non-hormonal oral compound NT-814 to alleviate menopausal symptoms / Development compound recently completed Phase IIb / Reinforces Bayer’s position in Women’s Healthcare / Upfront consideration of USD 425 million and additional potential consideration in the form of milestone payments » more
-
Thursday - August 6, 2020
Bayer stands by Kenya and Uganda in fight against desert locust devastation
Insecticide donation enables treatment of 170,000 hectares of the most affected fields » more
-
Tuesday - August 4, 2020
Second quarter of 2020:
Bayer: Solid performance despite COVID-19 impact
Ensuring employee safety and maintaining supply chains remain top priorities / Group sales decline by 2.5 percent (Fx & portfolio adj.) to 10.054 billion euros / EBITDA before special items up 5.6 percent to 2.883 billion euros / Crop Science reports operational growth / Sales and earnings at Pharmaceuticals down mainly due to volume-based procurement policy in China and COVID-19 / Sales at Consumer Health decline slightly (Fx & portfolio adj.) after strong demand in first quarter / Net loss of 9.548 billion euros due to special items for litigations – agreements in major legacy Monsanto litigation / Core earnings per share increase by 5.3 percent to 1.59 euros / Free cash flow rises to 1.402 billion euros / Outlook adjusted for COVID-19 impact » more
-
Monday - August 3, 2020
Bayer completes the sale of its Animal Health business unit to Elanco » more
-
Tuesday - July 21, 2020
Bayer takes steps to make carbon sequestration a farmer’s newest crop opportunity
Bayer to reward growers to generate carbon credits by adopting climate-smart practices and creating a new revenue stream on-farm / The initiative makes Bayer the first company to develop a transparent, science-based and collaborative approach to a carbon market in agriculture » more
-
Thursday - July 16, 2020
Not intended for U.S. and UK Media
U.S. FDA grants priority review to New Drug Application for vericiguat to treat chronic heart failure » more
-
Wednesday - July 15, 2020
Not intended for U.S. and UK Media
Bayer and Siemens Healthineers Present First Synchronized Imaging System Interface for MRI
The Imaging System Interface (ISI) saves time, improves operational efficiency and reduces the number of steps in the MRI workflow by one third, allowing the user to focus more on the patient / ISI recently achieved CE mark certification / Joint hardware and software development by Bayer and Siemens Healthineers » more
-
Thursday - July 9, 2020
Bayer partners with Prospera Technologies Inc. to develop integrated digital solutions for vegetable greenhouse growers
Strategic collaboration to create transformational tool based on data insights and AI / Initial roll-out to begin in Mexico vegetable greenhouses in July 2020 » more
-
Thursday - July 9, 2020
Not intended for U.S. and UK Media
Bayer’s finerenone meets primary endpoint in Phase III FIDELIO-DKD renal outcomes study in patients with chronic kidney disease and type 2 diabetes
Finerenone significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care / Finerenone significantly reduced the combined key secondary endpoint of cardiovascular death or non-fatal cardiovascular events / Chronic kidney disease impacts 4 in 10 patients with type 2 diabetes and is a deadly condition that is underrecognized / Finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor antagonist to demonstrate renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes / Bayer will discuss the data with health authorities regarding the submission of marketing authorization application » more
-
Wednesday - July 8, 2020
Bayer remains committed to Roundup™ settlement » more
-
Wednesday - July 1, 2020
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer issues new senior bonds with a volume of 6 billion euros
Issuance of four tranches with maturities between 4 and 12 years was substantially oversubscribed » more
-
Wednesday - June 24, 2020
Bayer announces agreements to resolve major legacy Monsanto litigation
Company will make a total payment of $10.1 billion to $10.9 billion (EUR 9.1 billion to EUR 9.8 billion) to resolve current and address potential future Roundup™ litigation / Company also resolves dicamba drift litigation for payment of up to $400 million and most PCB water litigation exposure for payment of approximately $820 million / Funding sourced from free cash flow and Animal Health divestment / Bayer is well positioned to deliver science-based solutions to meet global health, nutrition needs » more
-
Wednesday - June 24, 2020
Investor Conference Call
SPEECHES
Bayer announces agreements to resolve major legacy Monsanto litigation » more
-
Friday - June 19, 2020
Not intended for U.S. and UK Media
Bayer contributes an additional 50 million units of treatment to the World Federation of Hemophilia Humanitarian Aid Program
34 low-income countries are already benefiting from Bayer’s recombinant Factor VIII (FVIII) treatments since the start of the partnership with the World Federation of Hemophilia (WFH) in May 2019 / Bayer emphasizes that it will maintain its delivery of life-changing medicines to low-income countries / Bayer also renews its commitment to training and education as well as advocacy for patient access in low-income countries » more
-
Friday - June 19, 2020
Women empowerment in times of COVID-19
Bayer supports “The Challenge Initiative” of Johns Hopkins Bloomberg School of Public Health with 10 million USD
“The Challenge Initiative” to scale up reproductive health for women and girls in urban poverty areas / Participating cities in East Africa, Francophone West Africa, Nigeria, and India / Integrate COVID-19 prevention and education » more
-
Wednesday - June 17, 2020
Bayer to Provide Crop Relief to Two Million Smallholder Farmers Impacted by COVID-19
Through its new “Better Farms, Better Lives” initiative, Bayer will complement its current commitment to support smallholder farmers in key countries by donating seeds and crop protection inputs / The donations help boost food security by supporting up to two million smallholder farmers facing increased challenges as a result of the on-going COVID-19 pandemic » more
-
Wednesday - June 17, 2020
Not intended for U.S. and UK Media
Bayer to highlight latest research on its advancing Oncology portfolio at the AACR20 Virtual Annual Meeting II
Focus on Targeted Thorium Conjugate (TTC) platform, the company’s proprietary targeted alpha therapies program / Synergistic effects of investigational PSMA-TTC in combination with androgen receptor inhibitor darolutamide in preclinical prostate cancer » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Tuesday, April 27, 2021
Annual Stockholders' Meeting 2021
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV